Clinical studies have reported that HO-1 expression is increased in PCa patients, which correlates with high Gleason grade, increased serum prostate-specific antigen (PSA), resistance to therapy, and poor clinical outcome [21,29,30,31]. This evidence concerns the gene KLK3 and posterior cortical atrophy.